Archive for the ‘research’ Category

What the Mystery of the Tick-Borne Meat Allergy Could Reveal

https://www.nytimes.com/2018/07/24/magazine/what-the-mystery-of-the-tick-borne-meat-allergy-could-reveal.html

What the Mystery of the Tick-Borne Meat Allergy Could Reveal

Unraveling why tick bites are suddenly causing a strange reaction in some people who eat meat could help scientists better understand how all allergies work.

By Moises Velasquez-Manoff

One spring evening in 2016, Lee Niegelsky’s underarm began to itch. An investment manager, he was doing housework around his condo, and he thought he’d been bitten by a chigger. But within 15 minutes, hives had erupted all over his body. He responded with what he calls a “typical man reaction” — if the hives didn’t clear up by the next day, he would have them checked. Fifteen minutes later, the itch had become unbearable. He needed help right away.

His wife wasn’t home, so he drove himself to the university hospital emergency room near where he lived in Chapel Hill, N.C. As he explained his symptoms at the check-in counter, he began to feel faint, then fell to one knee. An orderly offered a wheelchair. He sat down — and promptly lost consciousness.  (See link for article)

______________

**Comment**

I find it interesting that no one is mentioning the fact ticks have been tweaked in a lab for biowarfare purposes.  

https://madisonarealymesupportgroup.com/2018/03/07/hantavirus-tularemia-warnings-issued-in-san-diego-county/  Tularemia, brucella, certain Rickettsia’s, numerous viruses, some chlamydia’s, and of course mycoplasma have all been weaponized.  https://madisonarealymesupportgroup.com/2015/08/12/connecting-dots-mycoplasma/

http://www.immed.org/infectious%20disease%20reports/InfectDiseaseReport06.11.09update/PHA_Nicolson_0709_v4.07.pdf

“According to Dr. Nicolson, some of the experiments used Mycoplasma while others utilized various “cocktails of microbial agents” such as Mycoplasma, Brucella, and DNA viruses such as Parvovirus B19. This project later become the topic of a book by Dr. Nicolson entitled Project Day Lily.

Dr. Nicolson believes that Mycoplasma fermentans is a naturally occurring microbe. However, some of the strains that exist today have been weaponized. Dr. Nicolson’s research found unusual genes in M. fermentans incognitus that were consistent with a weaponized form of the organism. Weaponzing of an organism is done in an attempt to make a germ more pathogenic, immunosuppressive, resistant to heat and dryness, and to increase its survival rate such that the germ could be used in various types of weapons. Genes which were part of the HIV‐1 envelope gene were found in these Mycoplasma. This means that the infection may not give someone HIV, but that it may result in some of the debilitating symptoms of the HIV disease.”

Regarding the weaponization of tick pathogens:  https://www.lymedisease.org/lymepolicywonk-questioning-governments-role-lyme-disease-make-conspiracy-theorist/  (Go here to read excerpts of an interview with a biologist who acknowledged doing biowarfare work on ticks and mosquitoes.  He admits every time he has a strange illness his physician says it’s probably a rickettsia – an idiopathic condition that never tests positive but symptoms indicate it.)

‘The interview suggests to me that the reason we have such a large problem with our tick population today may be related to military experiments in the 50s. They were part of a biological warfare effort against the Russians. One goal was to figure out how to get ticks to reproduce quickly and abundantly, as well as how to distribute ticks to targeted areas.”

For a lengthy but informative read on the Lyme-Biowarfare connections:  CitizensAlert_Bob13  (Scroll to page 44 to see an executive summary.  Please notice the names of Steere, Barbour, Shapiro, Klempner, and Wormser, the first four are affiliated with the CDC Epidemic Intelligence Service (EIS).  Wormser, lead author of the fraudulent Lyme treatment guidelines, lectures as an expert on biowarefare agents and treatments).  The author of the pdf believes borrelia (Lyme) has been bioweaponized due to (excerpt from pdf footnote):

226 An article was put out by the Associated Press mentioning the study of Lyme disease at a new biowarfare lab at the University of Texas, San Antonio. The article was quickly retracted and mention of Lyme disease was scrubbed from the article. Here is the text of the original article: “A new research lab for bioterrorism opened Monday at the University of Texas at San Antonio. The $10.6 million Margaret Batts Tobin Laboratory Building will provide a 22,000-square-foot facility to study such diseases as anthrax, tularemia, cholera, lyme disease, desert valley fever and other parasitic and fungal diseases. The Centers for Disease Control and Prevention identified these diseases as potential bioterrorism agents.” MSNBC, 11/21/2005. For a comparison of the censored and uncensored articles, see: http://members.iconn.net/~marlae/lyme/featurearticle02.htm

So you tell me.  Could all this lab tweaking have something to do with tick borne illness and allergies?

Category:

Activism, Alpha Gal Meat Allergy, Malaria, Parasites, research, Testing, Ticks

Herpes Viruses Implicated in Alzheimer’s Disease

https://www.the-scientist.com/news-opinion/herpes-viruses-implicated-in-alzheimer-s-disease-64246#.W1VYqg-Tels.linkedin

Herpes Viruses Implicated in Alzheimer’s Disease

SAM GANDY, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

Herpes Viruses Implicated in Alzheimer’s Disease

A new study shows that the brains of Alzheimer’s disease patients have a greater viral load, while another study in mice shows infection leads to amyloid-β build up.

Jun 21, 2018, Anna Azvolinsky

 

The brains of Alzheimer’s disease patients have an abnormal build up of amyloid-β proteins and tau tangles, which, according to many researchers, drives the ultimately fatal cognitive disease. This theory is being challenged by a newer one, which posits that microbes may trigger Alzheimer’s pathology.

Two new studies, using different approaches, further bolster this pathogen theory. Analyzing the transcriptomes of post-mortem brain samples from patients with Alzheimer’s disease, one group of researchers finds that two strains of human herpesvirus are significantly more abundant than in the brains of people of the same age without Alzheimer’s disease. Gene networks in the brains of Alzheimer’s patients with these strains are also rewired such that disease-related genes are differentially expressed compared to controls.

In the other study, another team of investigators observed in mouse models and in a three-dimensional human neuronal cell culture that a Herpseviridae infection could seed amyloid-β plaques. 

“These two papers add to a weight of evidence that viruses—and pathogens in general—must now be seriously considered as causal agents in Alzheimer’s disease,” Chris Carter, who studies the genetics and epidemiology of Alzheimer’s and other neurological disorders at Polygenic Pathways in the U.K., tells The Scientist.

Over three decades, there have been accumulating data from human studies suggesting that certain microbes, namely, viruses bacteria and fungi, may trigger or promote Alzheimer’s pathology in the aging brain. 

See “Do Microbes Trigger Alzheimer’s Disease?”

The Mount Sinai group initially set out to mine their RNA and DNA sequencing data from Alzheimer’s brain samples for drug targets. Then they found these viral sequences that were difficult to ignore. “I recently gave a talk that I titled, ‘I went looking for drugs but all I found was these viruses,’” study coauthor Joel Dudley, a genomics researcher at the Icahn School of Medicine at Mount Sinai, tells The Scientist.

In their study of elderly human brains, Dudley and the team from Mount Sinai sequenced more than 1,400 post-mortem brain samples, finding the first evidence that human herpesviruses 6A (HHV-6A) and 7 (HHV-7) are in greater abundance in regions of the brain including the superior temporal gyrus, anterior prefrontal cortex, and dorsolateral prefrontal cortex.

These data suggest that multiple pathogens, and not just these viruses, likely contribute to Alzheimer’s disease. 

—Chris Carter, Polygenic Pathways

Using RNA and DNA sequencing data, the team computationally generated regulatory network models that implicated the presence these viruses in altering the activity of genes linked to Alzheimer’s risk.

The researchers turned to one of the microRNAs, miR-155, found in their analysis to be suppressed by HHV-6A in the human samples, to see what the functional consequence is of this interaction. They homed in on miR-155 because it was a novel microRNA and because it had been previously linked to herpes viruses. When they knocked out the gene for miR-155 in a mouse model of Alzheimer’s disease, the animals’ brains had larger amyloid plaques and higher levels of amyloid-β compared to the mouse model with a wildtype MIR155 gene.

“Conceivably, the viral proteins are acting as transcription factors that control expression of Alzheimer’s risk genes,” coauthor Sam Gandy, a professor of neurology who specializes in Alzheimer’s disease at Mount Sinai, writes in an email to The Scientist. “Perhaps this viral dysregulation of Alzheimer’s genes that we see promotes the Alzheimer’s pathology of amyloid beta aggregation, inflammation and tau tangles,” he says.

The results, published today (June 21) in Neuron, could pave the way to new intervention strategies. “If established that these viruses indeed play a role in the development of Alzheimer’s, retroviral agents should be tested as a potential therapy,” says Dudley.

In the other study, available as a preprint on the Cell website and in Neuron July 11, Rudolph Tanzi and Robert Moir, both researchers at Harvard Medical School and Massachusetts General Hospital, and their colleagues tested how amyloid-β in the brain—which these labs previously found to be an antimicrobial—reacts to herpes simplex virus 1 (HSV1), HHV6A, and HHV6B. These strains all tend to integrate into the genomes of neurons. They found that in a culture of human neuronal cells, amyloid-β could prevent HSV1 infection and can bind and aggregate the HSV1 and HHV6 viruses. Mice infected with HSV1—which can cause encephalitis—that also had genetically elevated amyloid-β expression were protected against encephalitis, but also had increased amyloid deposits.

“These studies further add to the steadily increasing number of papers that support a microbial role in Alzheimer’s disease,” Ruth Itzhaki, a molecular neurobiologist at the University of Manchester in the U.K. who studies the link between viruses and the development of Alzheimer’s disease, writes in an email to The Scientist.

A recent epidemiology study adds real-world credence to the microbial link to Alzheimer’s. A population study in Taiwan examined more than 33,000 individuals and found that those with a herpes simplex virus infection had a 2.5-fold greater risk of developing Alzheimer’s disease. The study authors found that in those people treated with antiherpes medications, the 2.5-fold risk dropped back down to baseline. 

“The conclusion you can draw is that the antiherpes medication reduced the risk of Alzheimer’s by keeping the herpes infection in check,” says Moir.

Itzhaki agrees. This study and two others, also from Taiwan, appear to link HSV1 causally to Alzheimer’s disease, she writes. “Despite various shortcomings, these Taiwan studies are the essential first steps to a proof that a microbe could be the cause of a non-infectious disease, in this case, Alzheimer’s.” Itzhaki and a colleague wrote about these studies recently in a commentary, which aimed to interpret the “important and surprising Taiwan data” on the effectiveness of the antiviral treatment, Itzhaki tells The Scientist.

Carter cautions that the new reports should not be interpreted to mean that there is likely a single, unique Alzheimer’s pathogen, if there is one at all. “These data suggest that multiple pathogens, and not just these viruses, likely contribute to Alzheimer’s disease. It is also likely that the pathogens may vary between Alzheimer’s patients.”

The Mount Sinai team will now be verifying whether HHV6 and HHV7 are actually integrated into the genomes of Alzheimer’s patients’ brains and testing for the presence of HHV6 and HHV7 in the bloodstream and central nervous system of Alzheimer’s patients. They would like to do a study comparing living patients and controls to see if the link they observed between the viruses’ presence and changes in gene regulation related to Alzheimer’s holds up.

Tanzi’s and Moir’s labs are focusing on the role of the brain microbiome in Alzheimer’s disease. Comparing the brains of older and younger individuals, including those with Alzheimer’s, their preliminary evidence shows that the brain microbiome—which contains hundreds of bacterial and fungal species—is shifted and linked to pro-inflammatory activity. “It’s analogous to what happens with the gut microbiome in individuals with irritable bowel syndrome,” says Moir. “Our model right now is that it’s not just a single microbe, but a disturbance in the brain microbiome that can lead to Alzheimer’s disease.”

B. Readhead et al., “Multi-scale analysis of independent Alzheimer’s cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus,” Neuron, doi.org/10.1016/j.neuron.2018.05.023, 2018.

W.A. Eimer et al. “Alzheimer’s disease-associated β-amyloid is rapidly seeded by herpesviridae to protect against brain infection,” Neuron, in press, July 12, 2018.

Correction (June 21): We removed two sentences in paragraph seven. One noted the prevalence of virus in diseased brains, but did not note that the prevalence is the same in control brains. The other sentence misstated the regions of the brain where the viruses were in greater abundance compared to control brains and stated these brain regions were linked to Alzheimer’s disease. The Scientist regrets the error.

________________

**Comment**

  1.  Lyme/MSIDS patients often have viral involvement – particularly herpes strains
  2. The role of bacteria, viruses, and fungus is important and likely includes the very things Lyme/MSIDS patients have and are being treated for.
  3. This article points out another reason to take treatment for Lyme/MSIDS seriously.  If left unchecked, Lyme/MSIDS can possibly be a perfect storm for Alzheimer’s later.

For more:  https://madisonarealymesupportgroup.com/2017/01/18/a-bug-for-alzheimers/

https://madisonarealymesupportgroup.com/2016/06/09/alzheimers-byproduct-of-infection/

https://madisonarealymesupportgroup.com/2016/11/17/antibiotics-and-alzheimers/

https://madisonarealymesupportgroup.com/2016/06/03/borrelia-hiding-in-worms-causing-chronic-brain-diseases/

https://madisonarealymesupportgroup.com/2018/03/25/a-brief-history-of-neuroborreliosis-research-dementia-an-inside-look-at-two-researchers/

https://madisonarealymesupportgroup.com/2017/06/10/the-coming-pandemic-of-lyme-dementia/

https://madisonarealymesupportgroup.com/2016/11/17/alzheimers-lyme/

Dr. David Baewer discusses arboviruses & Lyme:  https://madisonarealymesupportgroup.com/2016/06/07/dr-david-baewer-coppe-labs/ Coppe Labs, in Wisconsin, provides advanced testing for leukotropic herpesviruses: EBV, CMV, HHV-6A and HHV-6B, as well as tick-borne pathogens, and their tests distinguish between latent and active infections.

 

 

Category:

Alzheimer's, Inflammation, Lyme, Parasites, Psychological Aspects, research, Treatment, Viruses

Tuttle’s Response to the NEJM Article

Yesterday, I posted this:  https://madisonarealymesupportgroup.com/2018/07/26/tickborne-diseases-confronting-a-growing-threat/  (Please read the article in this link including my comments at the bottom before Tuttle’s response below so it will make more sense)

The one thing I didn’t deal with that I will point out now is this regurgitated number in the NEJM article of 10-20% of patients moving on to chronic/persistent Lyme.  The following informative article written by Lorraine Johnson points out this number to be considerably higher which corresponds to my experience as a patient advocate:  https://madisonarealymesupportgroup.com/2018/07/22/lyme-costs-may-exceed-75-billion-per-year/.  Excerpt below:

Besides the staggering financial cost to this 21st century plague, this paper, based on estimates of treatment failure rates associated with early and late Lyme, estimates that 35-50% of those who contract Lyme will develop persistent or chronic disease.

Let that sink in.

And in the Hopkins study found 63% developed late/chronic Lyme symptoms.
For some time I’ve been rankled by the repeated CDC statement that only 10-20% of patents go on to develop chronic symptoms. This mantra in turn is then repeated by everyone else.

While still an estimate, I’d say 35 to over 60% is a tad higher than 10-20%, wouldn’t you? It also better reflects the patient group I deal with on a daily basis. I can tell you this – it’s a far greater number than imagined and is only going to worsen.

Now for Tuttle’s response:

https://www.change.org/p/1120418/u/23062391?utm_medium=email&utm_source=petition_update&ut

PETITION UPDATE

Tickborne Diseases — Confronting a Growing Threat

Carl Tuttle
Hudson, NH
JUL 26, 2018 — Please see the letter below addressed to Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases (NIAID).

It would appear that the racketeering scheme to downplay the severity of Lyme disease is rampant throughout all government health agencies.

Letter to Anthony S. Fauci, M.D:

———- Original Message ———-
From: Carl Tuttle
To: Anthony.Fauci@nih.hhs.gov
Cc: catharine.paules@nih.hhs.gov, hilary.marston@nih.hhs.gov, Marshall.Bloom@nih.hhs.gov, comments@nejm.org, ddutko@hanszenlaporte.com, chris.smith@mail.house.gov, collin.peterson@mail.house.gov, jdrazen@nejm.org, info@massmed.org, president@massmed.org, mmsvp@massmed.org
Date: July 26, 2018 at 9:16 AM
Subject: Tickborne Diseases — Confronting a Growing Threat

Tickborne Diseases — Confronting a Growing Threat

Catharine I. Paules, M.D., Hilary D. Marston, M.D., M.P.H., Marshall E. Bloom, M.D., and Anthony S. Fauci, M.D. This article was published on July 25, 2018, at NEJM.org.
https://www.nejm.org/doi/full/10.1056/NEJMp1807870

Excerpt:

“Although most cases are successfully treated with antibiotics, 10 to 20% of patients report lingering symptoms after receiving appropriate therapy.”

July 26, 2018

Office of the Director,
National Institute of Allergy and Infectious Diseases (NIAID),
National Institutes of Health,
Bethesda, MD 20892
Attn: Anthony S. Fauci, M.D., Director

Dear Dr. Fauci,

There has been a thirty year fixation on the acute stage of Lyme disease (with bulls-eye rash) after early treatment however patients with a prolonged exposure to the pathogen before diagnosis and initial treatment are almost always incapacitated.

You know that untreated strep throat progresses to rheumatic fever causing irreversible heart damage. What happens to the Lyme patient who went months, years or decades before diagnosis? Dr. Neil Spector required a heart transplant after his Lyme went undiagnosed for four years while his laboratory tests (serology) were repeatedly negative. [1]

Singer/songwriter Kris Kristofferson was being treated for Alzheimer’s disease when discovering he had undiagnosed Lyme disease. [2]

Autopsy results identify the destructive nature of Borrelia as evident in Vicky Logan’s liver (nutmeg liver), kidneys, heart, lungs and brain. The patient died after the insurer refused additional IV antibiotic therapy. [3]

There is a growing patient population of this class of disabled patient who has been ignored for nearly four decades. Lyme disease is a life-altering/life-threatening infection misclassified as a low-risk and non-urgent health issue through an elaborate racketeering scheme as outlined in the SHRADER & ASSOCIATES, LLP racketeering lawsuit. [4] The U.S. Centers for Disease Control has aligned themselves with the seven defendants/academics named in this RICO lawsuit.
From your article:

“Nonserologic platform technologies may also improve diagnostic capabilities, particularly in identifying emerging pathogens. Two previously unknown tickborne RNA viruses, Heartland virus and Bourbon virus, were discovered by researchers using next-generation sequencing to help link organisms with sets of unexplained clinical symptoms.”

When Sanger sequencing identified a case of chronic Lyme disease, the CDC stopped all communication with the Director of Milford Molecular Diagnostics. [5], [6]

The recently published Middelveen paper reported persistent infection as the majority of patients were culture positive for infection even after multiple years on antibiotics so there was no relief from current antimicrobials. Some patients had taken as many as eleven different types of antibiotics. [7]
_______________________

Dr. Fauci; your “Perspective” published in the New England Journal of Medicine does not mention anything I have presented here so it would appear that you are caught up in this racketeering scheme to suppress the severity of a disease that is destroying lives, ending careers, causing death and disability while leaving victims in financial ruin. There are no Public Service Announcements informing the public that you could become horribly disabled or die from Lyme disease.

It is time to move Lyme disease to HIGHEST ALERT and remove the CDC’s stronghold over the progress to find a curative approach for the late stage Lyme epidemic. [8]

Acknowledgment and response to this letter is requested.

Respectfully submitted,

Carl Tuttle
Lyme Endemic Hudson, NH

Cc: Attorney Daniel Dutko of Hanszen Laporte
U. S. Representatives Chris Smith and Colin Peterson

 

Category:

Activism, Alzheimer's, Disability, Lyme, research, Ticks, Treatment

Congenital Transmission of Lyme – Myth or Reality?

https://dermagicexpress.blogspot.com/2018/07/congenital-transmission-of-erythema.html?m=1

July 22, 2018

CONGENITAL TRANSMISSION OF ERYTHEMA MIGRANS OR LYME DISEASE, MYTH OR REALITY ?

AUTHORS

1.) Dr. Lapenta, J Medic Surgeon, Specialty Dermatology, 24 years of exercise. Highly trained in the field of research; University of Carabobo, Venezuela. CEO DERMAGIC EXPRESS. www.dermagicexpress.blogspot.com

2.) Dr. Lapenta, JM. Medic Surgeon. University of Carabobo. Diplomat in Facial Aesthetics Occupational Medicine and Prehospital Auxiliary. Resident Doctor Ambulatorio Del Norte Maracay Aragua State. COO DERMAGIC EXPRESS.  www.dermagicexpress.blogspot.com

ABSTRACT

Lyme disease or Erythema Migrans, described many years ago, and previously known under the name of Lyme Juvenile Arthritis, is produced by a spirochete transmitted by the bite of a family tick. Ixodidade, Ixodes scapularis and many others; discovered by the scientist Willy Burgdorfer in the year of 1981, being named Borrelia Burgorferi, in honor of its discoverer. Apart from the numerous cutaneous and organic manifestations attributed to Borrelia, it is nowadays discussed in the scientific field if it is capable of crossing the placenta and causing fetal damage. In this review we will show you that this biological agent, as in syphilis, produced by Treponema Pallidum, another spirochete, crosses the placenta and can produce serious consequences to the fetus, including death.

Key words: Lyme disease, Borrelia burgdorferi, congenital lyme, fetal damage and pregnancy

MAIN OBJECTIVE

The main objective of this work is to demonstrate that Lyme disease and their biological agent, spirochete Borrelia Burgdorferi, is not only an illness with cutaneous manifestations. It can cross the placenta during pregnancy and produce fetal damage that in severe cases can cause death in newborns.

SECONDARY OBJECTIVES.

1.) Describe the clinical manifestations in children born from positive Lyme mothers who did not receive treatment in pregnancy, or in those who received treatment with resistance to it.

2.) Alert the World community that there is indeed transplacental transmission of Borrelia Burgdorferi in pregnant Lyme positive women and if there is not adequate treated in time, both the mother and fetus can present clinical symptoms ranging from mild, to severe, even stillbirth.

3.) To call attention to the World Health Organization so that in the revision of the international codes of diseases (ICD-11), this year 2018, the code “Congenital Lyme” be  included in them.

INTRODUCTION

The Center for Disease Control and Prevention (CDC) affirms in its website that the pregnant woman Lyme positive when making her treatment, the child will be born healthy and recommends for this, the use of the antibiotic amoxicillin or cefuroxime, because doxycycline, which is the antibiotic of choice, can cause damage to the developing fetus. [1]

Other antibiotics recommended by the CDC are the macrolides azithromycin, clarithromycin or erythromycin in case of allergy or intolerance to those previously mentioned. [2]

The CDC itself recognizes that Lyme disease and its causative agent Borrelia Burgdorferi can cross the placenta and cause stillbirths. [1-2]

The question here is what would happen if the Borrelia species, as in some cases, is resistant to amoxicillin or another antibiotic, or the antibiotic to which Borrelia is sensitive cannot be indicated because it would harm the fetus? And beyond, if the patient does not receive the treatment by omission or carelessness? [3]

As we said previously the Borrelia Burgdorferi was discovered by Willy Burgdorfer in the year 1981, and just two (2) year later, in 1983 the first study was published by Shirts SR, and Brown MS, Bobitt Jr, where it is suspected that this spirochete can cross the placenta. [4]

After this study others began to appear, who definitely showed that this spirochete is able to cross the placenta and cause fetal damage, of which we will present in chronological order the most important and confirm the above said.

CHRONOLOGICAL EVOLUTION

1983

The first suspicion described that ante partum fever may be caused by the Borrelia Burgdorferi species, was made in 1983 in two febrile pregnant women in the third-trimester. The two newborn survived, but the scientists suggested the establishment of early laboratory tests to identify the causative agent and the establishment of a rapid treatment to avoid future complications in the pregnant and the fetus. [4]

1985

Really, the first study describing the maternal-fetal transmission of Lyme disease, Borrelia Burgdorferi was published in 1985 by Schlesinger PA, Duray PH, Burke BA, Steere AC, and Stillman MT., Where they describe a case of a pregnant woman who acquired Lyme Borreliosis and did not receive treatment with antibiotics. The child was born at 35 weeks of pregnancy and died of congenital heart disease the first week of life. The autopsy revealed the Borrelia Burgdorferi spirochete in the spleen, kidneys and bone marrow. [5]

1986-1989

In the year 1986, MacDonald A, describes 4 cases of abortions in pregnant women who tested positive for Lyme, and in whose fetuses the Borrelia Burgdorferi was found in their tissues. This same author does another work in 1989 about Lyme disease and its implications for the fetus and describes side effects such as fetal death, hydrocephalus, cardiovascular abnormalities, neonatal respiratory distress, hyperbilirubinemia, intrauterine growth retardation, cortical blindness, sudden death syndrome of the infant and maternal toxemia of pregnancy, and raises the similarity of these with neonatal syphilis. [6-7].

1987

Later, the same Willy Burgdorfer the discoverer of the Borrelia Burgdorferi, together with Dr. Alan Mc Donald and Jorge Benach PhD, published in year 1987 (31 years ago) a work where they relate this disease with children born dead associated in pregnant Lyme positive.

Among the highlights the description of congenital malformations, fetal death, cardiac anomalies and alert the scientific community to investigate exposure during the first trimester of pregnancy in the presence of Borrelia Burgdorferi; and in this cases to determine if cardiac organogenesis is complete by the end of the first trimester of pregnancy. They also recommend starting treatment with Penicillin at the same dose of syphilis in those cases of pregnant women who show signs and early symptoms of the disease. [8]

1988-2012

In these 24 years a total of more than 80 papers were published where Lyme disease is effectively related to pregnancy with fetal damage, studies done in the countries: United States, Canada, Hungary, Germany, Italy, Switzerland, Africa, Turkey, Czech Republic, Poland and Belgrade former Yugoslavia, and others [10-52]

Another study that is worth noting is that carried out by the updated MEDLINE database for the year of July 2012, the last revision of November 2012 of 88 journal articles from the PUBMED database, which we summarize in this way

Maternal-fetal transmission of Lyme disease (Findings):

1.) Mothers with active Lyme disease, treated: 14.6% of pregnancies resulted in sequel (a morbid condition following or occurring as a consequence of having Lyme).

2.) Mothers with active Lyme disease not treated: 66.7% of pregnancies resulted in sequel.

3.) Positive Lyme mothers, the treatment is unknown: 30.3% resulted in sequel.

4.) Specific adverse results included:

– Cardiac 22.7%,

– Neurological 15.2%,

– Orthopedic 12.1%,

– Ophthalmologic 4.5%,

– Genitourinary 10.6%,

– Miscellaneous anomalies 12.1%. [53]

Now we will put a summary of the most frequent clinical manifestations described in a study of more than 100 children born to mothers with LYME positive disease, conducted in the year 2005.

COMMON SIGNS AND SYMPTOMS IN LYME POSITIVE CHILDREN:

1.) Low grade fever: 59% -60%
2.) Fatigue and lack of resistance: 72%
3.) Nocturnal sweating: 23%
4.) Pale, dark circle under the eyes: 42%
5.) Abdominal pain: 20-29%
6.) Diarrhea or constipation: 32%
7.) Nausea: 23%
8.) Cardiac anomalies: 23%: palpitations / PVC, heart murmur, mitral valve prolapse.
9.) Orthopedic disorders: sensitivity (55%), pain (69%) spasms and generalized muscle pain (69%), rigidity and / or retarded motion (23%).
10.) Respiratory infections of the superior tract and otitis: 40%
11.) Arthritic disorders and painful joints: 6% -50-%
12.) Neurological disorders:
A- Headaches: 50%
B-) Irritability: 54%.
C-) Bad memory: 39%
13.) Delay in development: 18%
14.) Seizure disorder: 11%
15.) Vertigo: 30%
16.) Tic disorders: 14%
17.) Involuntary athetoid movements: 9%.
18.) Earning disorders and humor changes: 80%
A-) Cognitive speaking: 27%
B-) Speech delay: 21%
C-) Reading-writing problems: 19%
D.) Problems of vocal articulation: 17%.
E-) Auditory / visual processing problems: 13%
F-) Word selection problems: 12%
G-) Dyslexia: 8%
19.) Suicidal thoughts: 7%
20.) Anxiety: 21%
21.) Anger or rage: 23%
22.) Aggression or violence: 13%
23.) Irritability: 54% -80%
24.) Emotional disorders: 13%
25.) Depression: 13%
26.) Hyperactivity: 36%
27.) Photophobia: 40-43%
28.) Gastroesophageal reflux with vomiting and coughing: 40%
29.) Secondary eruptions: 23%
30.) Other eruptions: 45%
31.) Cavernous haemangioma: 30%
32.) Ocular problems: posterior cataracts, myopia, stigmatism, conjunctive erythema (Lyme eyes), optical nerve atrophy and / of uveitis: 30%
33.) Sensitivity of skin and noise (hyperacuity): 36-40%
46.) Autism: (9%). [41]

2013-2018

In recent years the number of cases of Lyme disease has increased notably in North America, Europe, Asia and Africa; in the United States and Canada, it is the most commonly transmitted vector-borne disease reported today [54-62].

For the year 2017 the World Health Organization (WHO) in charge of “coding” diseases through the ICD-10 (International Classification of Diseases year 2.017), had not yet included and recognized the code “Congenital Lyme”. It is expected for this year 2018 that all codes of Lyme disease will be recognized by this organization. [63-68]

You can read this classification and codes here:  UNDERSTANDIG THE LYME DISEASE CLASSIFICATION AND CODES. [69]

CONCLUSIONS

1.) Lyme disease is caused by the bite of a tick transmitted by the Borrelia Burgdorferi spirochete, discovered by Willy Burgdorfer in the year 1981. Initially, skin, joint and cardiac manifestations were described in those affected, but not in pregnant women or the fetus.

2.) Two years later, in 1983, was described the suspicion of infection in pregnant women, and in 1985 it was found the first clinical manifestations in pregnant women and fetuses, highlighting congenital malformations and fetal death.

3.) We demonstrate scientifically that definitely Lyme disease, in addition to its multiple organic manifestations, its causative agent Borrelia Burgdorferi, crosses the placenta and reaches the fetus in pregnant women, producing the side effects already described.

4.) All pregnant women living in endemic areas of Lyme disease should take the tests to rule out Borreliosis of pregnancy, to establish immediate treatment in case of being positive.

5.) In addition to establishing adequate treatment, we alert the population to defend against the bite of possibly infected ticks.

6.) We urge the World Health Organization to recognize all the codes and classification of Lyme disease in ICD-11 (International Classification of Diseases year 2.018).

ACKNOWLEDGMENTS

To the community of patients affected by Lyme disease.

To the organizations that fight for the recognition of this pathology as a public health problem World.

__________________

**Comment**

The Lyme community owes a debt of gratitude to the doctors Lapenta.  You will see many of their articles on my website as they have painstakingly combed through the research and condensed it for laypeople to clearly see the ramifications of Lyme and other tick borne illnesses.

This article makes plain that Lyme can be passed congenitally to infants.

For more on pregnancy with Lyme:

https://madisonarealymesupportgroup.com/2018/06/19/33-years-of-documentation-of-maternal-child-transmission-of-lyme-disease-and-congenital-lyme-borreliosis-a-review/

https://madisonarealymesupportgroup.com/2018/02/26/transplacental-transmission-fetal-damage-with-lyme-disease/

https://madisonarealymesupportgroup.com/2018/05/24/new-berlin-mom-given-life-altering-lyme-disease-diagnoses-after-pregnancy/

https://madisonarealymesupportgroup.com/2017/10/15/pregnancy-in-lyme-dr-ann-corson/

 

 

 

Category:

Activism, Lyme, Pregnancy, research, Transmission, Treatment

2018 ILADS Annual Conference in Chicago

Chicago Banner

Conference Registration Open!

Please join us for the International Lyme and Associated Diseases Society (ILADS) 19th Annual Conference. This year’s conference will be held on November 1-4, 2018, at the Sheraton Grand Chicago in downtown Chicago, IL. ILADS is delighted to meet in the Midwest for the first time.

 

The conference theme is Tick-Borne Diseases and the Immune System.

Thursday, November 1, 2018

  • Lyme Fundamentals
  • Experimental Treatments for Tick-Borne Diseases
  • Social – Theatrical performance about Lyme disease plus a demonstration of Hand Pans with a reception sponsored by IGeneX. Guests of registrants are welcome to attend this event.

ILADS Committee meetings also will be held.

On Thursday evening, November 1, 2018, IGeneX is sponsoring our theater event  featuring A BEAUTIFUL DANCE OF LIFE & DEATH, a true story of surviving Lyme disease.  The play is written by Erin R Hartnett, directed by Nicholas Collett, and performed by Sam Wright and Meredith Lindsay.  A reception follows the performance, which will feature ILADS own Dayna Wolfe, MD, who will be demonstrating Hand Pans to raise funds for ILADEF.  Come by to see what this is all about. Never heard of Hand Pans?  https://www.youtube.com/watch?v=6oremFnbgO0. Tickets are available for yourself and guests; space is limited.

We again are offering the Lyme Fundamentals course for practitioners who want to brush up their clinical skills and for those who are new to treating Lyme disease. This one-day track gives specific step-by-step guidance with ample opportunity to ask questions of the expert faculty. CME credits will be offered for this track. This session is for medical professionals only. There are a limited number of grants available to reimburse the registration fee for first time attending professionals.

We also are offering a day-long track called Experimental Treatments for Tick-Borne Diseases, which will look at promising new treatment options for Lyme patients. (Due to the evolving treatment modalities discussed, no CME will be given for this track.)

The Scientific Conference on Friday, November 2, 2018, through Sunday, November 4, 2018, will include the following:

  • Plenary Sessions – mornings Friday through Sunday
  • Breakout Sessions – Friday and Saturday afternoons
  • Poster Sessions – Friday morning through Sunday morning
  • Pioneer in Lyme Award Dinner – Friday evening social event honoring Kenneth B. Liegner, MD
  • Annual Members’ meeting Saturday late afternoon

The Scientific Conference schedule will extend from Friday morning to Sunday noon. Course Director Mualla McManus, PharmD, and her committee have planned a series of provocative lectures which will help you develop insights on the role of the immune system in the treatment of tick-borne diseases. Highly-regarded researchers and clinicians will share cutting-edge information during the plenary sessions and more topic-specific breakout sessions. CME will be offered for the entire Scientific Conference. We expect this conference to sell out, so please register as soon as possible and book your room at our conference hotel at our conference rate.

Chicago Conference Information:  www.ilads.org/ilads-conference/chicago-2018/
2018 ILADEF Pioneer Award Dinner:  https://customer274405b6f.portal.membersuite.com/events/ViewEvent.aspx?

The Pioneer in Lyme Award dinner (on Friday, November 2nd) will honor the lifetime achievement of Kenneth B. Liegner, MD, a past Board member of ILADS. Dr. Liegner is well known in the medical community for his intellectual vigor and personalized treatment protocols. Please join us for an elegant dinner featuring midwestern-inspired fare. The Jazz Ensemble, AS IS, will also provide entertainment.

rsz_ken2
Kenneth Liegner, MD, is a board-certified Internist with additional training in Pathology and Critical Care Medicine, practicing in Pawling, New York.  He has been actively involved in the diagnosis and treatment of Lyme disease and related disorders since 1988.  He has published articles on Lyme disease in peer-reviewed scientific journals and has presented poster abstracts and talks at national and international conferences on Lyme and other tick-borne diseases.  He has cared for many persons seriously ill with chronic and neurologic Lyme disease.  His work has focused on the serious morbidity and (occasional) mortality that can eventuate from this aspect of the illness.  He has emphasized the urgent need for the widespread clinical availability of improved methods of diagnostic testing and for the development of improved methods of treatment for Lyme disease in all its stages.  He holds the first U.S. patent issued proposing the application of acaricide to deer for area-wide control of deer-tick populations as a means of reducing the incidence of Lyme disease.  ILADEF invites you to join us for this prestigious event where you will have the opportunity to engage with some of the world’s leading Lyme disease researchers and clinicians as we join together to honor Dr. Liegner and address the number one vector-borne epidemic worldwide.

More on Liegner:  https://madisonarealymesupportgroup.com/2017/03/09/remember-vicki-logan/

50+ exhibitors will be on-site from Thursday morning through Sunday noon, showcasing products and services relevant to medical professionals who treat tick-borne diseases.

Category:

Activism, Lyme, research, Treatment